Ab­b­Vie ad­vances its two star pipeline ther­a­pies, fil­ing BLA for risankizum­ab and post­ing promis­ing da­ta for upadac­i­tinib

→ Ab­b­Vie racked up an­oth­er round of promis­ing da­ta for its late-stage rheuma­toid arthri­tis drug upadac­i­tinib. All three dos­es — 7.5 mg, 15 mg and 30 mg — in their Phase IIb/III study in Japan met the pri­ma­ry end­point of ACR20 ver­sus place­bo. And there were no ma­jor car­dio events to speak in­vestors this time, with no deaths, no events of pul­monary em­bolism or deep vein throm­bo­sis re­port­ed. Ab­b­Vie has high hopes for this drug, which is com­pet­ing against some ma­jor league ri­vals. The bio­phar­ma com­pa­ny has pegged peak po­ten­tial sales at $6.5 bil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER